Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
1. A pharmaceutical composition comprising:
an anti-HERV-W Env humanized monoclonal IgG4 antibody comprising (i) a light chain variable region including each of the CDRs set forth in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, and (ii) a heavy chain variable region including each of the CDRs set forth in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6; and
a Nitric Oxyde radical (NO) inhibitor selected from the group consisting of S-methyl-isothiourea (SMT) and dimethyl fumarate (DMF).
2. The pharmaceutical composition of claim 1 , wherein the NO inhibitor is SMT.
3. The pharmaceutical composition of claim 1 , wherein the NO inhibitor is DMF.
4. A pharmaceutical combination product comprising:
a first pharmaceutical composition comprising an anti-HERV-W Env humanized monoclonal IgG4 antibody comprising (i) a light chain variable region including each of the CDRs set forth in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, and (ii) a heavy chain variable region including each of the CDRs set forth in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6; and
a second pharmaceutical composition comprising a Nitric Oxyde radical (NO) inhibitor selected from the group consisting of S-methyl-isothiourea (SMT) and dimethyl fumarate (DMF).
5. The pharmaceutical combination product of claim 4 , wherein the NO inhibitor is SMT.
6. The pharmaceutical combination product of claim 4 , wherein the NO inhibitor is DMF.